Ken Griffin Atossa Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.09 - $1.52 $27,250 - $38,000	25,000 Added 58.69%	67,600 $102,000
Q2 2024 Aug 14, 2024	SELL	$1.03 - $2.1 $11,948 - $24,360	-11,600 Reduced 21.4%	42,600 $50,000
Q1 2024 May 15, 2024	BUY	$0.8 - $1.89 $27,040 - $63,882	33,800 Added 165.69%	54,200 $97,000
Q4 2023 Feb 14, 2024	SELL	$0.63 - $0.98 $3,402 - $5,292	-5,400 Reduced 20.93%	20,400 $17,000
Q3 2023 Nov 14, 2023	SELL	$0.74 - $1.35 $22,792 - $41,580	-30,800 Reduced 54.42%	25,800 $19,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.28 $4,020 - $8,576	-6,700 Reduced 10.58%	56,600 $71,000
Q1 2023 May 15, 2023	SELL	$0.59 - $0.91 $19,942 - $30,758	-33,800 Reduced 34.81%	63,300 $45,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $11,300 - $22,826	-22,600 Reduced 18.88%	97,100 $51,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.14 $738 - $1,026	900 Added 0.76%	119,700 $100,000

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.